Annual EBITDA
-$77.40 M
-$53.24 M-220.30%
December 31, 2024
Summary
- As of March 9, 2025, ARCT annual EBITDA is -$77.40 million, with the most recent change of -$53.24 million (-220.30%) on December 31, 2024.
- During the last 3 years, ARCT annual EBITDA has risen by +$124.26 million (+61.62%).
- ARCT annual EBITDA is now -664.81% below its all-time high of $13.70 million, reached on December 31, 2022.
Performance
ARCT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$17.85 M
-$8.03 M-81.69%
December 31, 2024
Summary
- As of March 9, 2025, ARCT quarterly EBITDA is -$17.85 million, with the most recent change of -$8.03 million (-81.69%) on December 31, 2024.
- Over the past year, ARCT quarterly EBITDA has dropped by -$1.39 million (-8.47%).
- ARCT quarterly EBITDA is now -115.06% below its all-time high of $118.52 million, reached on December 31, 2022.
Performance
ARCT Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$69.68 M
-$51.48 M-282.83%
December 31, 2024
Summary
- As of March 9, 2025, ARCT TTM EBITDA is -$69.68 million, with the most recent change of -$51.48 million (-282.83%) on December 31, 2024.
- Over the past year, ARCT TTM EBITDA has dropped by -$42.81 million (-159.38%).
- ARCT TTM EBITDA is now -160.01% below its all-time high of $116.11 million, reached on March 31, 2023.
Performance
ARCT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ARCT EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -220.3% | -8.5% | -159.4% |
| 3 y3 years | +61.6% | +47.6% | +51.7% |
| 5 y5 years | -216.5% | +47.6% | +51.7% |
ARCT EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -664.8% | +61.6% | -115.1% | +65.2% | -160.0% | +65.5% |
| 5 y | 5-year | -664.8% | +61.6% | -115.1% | +67.8% | -160.0% | +65.5% |
| alltime | all time | -664.8% | +61.6% | -115.1% | +67.8% | -160.0% | +65.5% |
Arcturus Therapeutics Holdings EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$77.40 M(+220.3%) | -$17.85 M(+81.7%) | -$69.68 M(+282.8%) |
| Sep 2024 | - | -$9.82 M(-40.3%) | -$18.20 M(-32.2%) |
| Jun 2024 | - | -$16.46 M(-35.6%) | -$26.86 M(-56.4%) |
| Mar 2024 | - | -$25.55 M(-176.0%) | -$61.64 M(-483.3%) |
| Dec 2023 | -$24.16 M(-276.3%) | $33.63 M(-281.9%) | $16.08 M(-84.1%) |
| Sep 2023 | - | -$18.49 M(-63.9%) | $100.97 M(+18.3%) |
| Jun 2023 | - | -$51.24 M(-198.2%) | $85.37 M(-26.5%) |
| Mar 2023 | - | $52.18 M(-56.0%) | $116.11 M(+747.3%) |
| Dec 2022 | $13.70 M(-106.8%) | $118.52 M(-447.7%) | $13.70 M(-109.5%) |
| Sep 2022 | - | -$34.08 M(+66.3%) | -$144.31 M(-11.6%) |
| Jun 2022 | - | -$20.50 M(-59.2%) | -$163.31 M(-16.8%) |
| Mar 2022 | - | -$50.23 M(+27.2%) | -$196.39 M(-2.6%) |
| Dec 2021 | -$201.66 M(+186.3%) | -$39.50 M(-25.6%) | -$201.66 M(+4.6%) |
| Sep 2021 | - | -$53.08 M(-0.9%) | -$192.81 M(+20.3%) |
| Jun 2021 | - | -$53.58 M(-3.4%) | -$160.32 M(+37.5%) |
| Mar 2021 | - | -$55.49 M(+81.1%) | -$116.59 M(+65.5%) |
| Dec 2020 | -$70.44 M(+188.0%) | -$30.64 M(+48.8%) | -$70.44 M(+39.8%) |
| Sep 2020 | - | -$20.59 M(+109.0%) | -$50.39 M(+36.8%) |
| Jun 2020 | - | -$9.86 M(+5.5%) | -$36.84 M(+35.0%) |
| Mar 2020 | - | -$9.34 M(-11.8%) | -$27.29 M(+11.6%) |
| Dec 2019 | -$24.45 M(+16.3%) | -$10.60 M(+50.4%) | -$24.45 M(+68.4%) |
| Sep 2019 | - | -$7.05 M(+2233.1%) | -$14.52 M(+24.4%) |
| Jun 2019 | - | -$302.00 K(-95.4%) | -$11.67 M(-45.3%) |
| Mar 2019 | - | -$6.51 M(+886.2%) | -$21.34 M(+0.2%) |
| Dec 2018 | -$21.02 M | -$660.00 K(-84.3%) | -$21.29 M(-17.3%) |
| Sep 2018 | - | -$4.20 M(-57.9%) | -$25.75 M(+4.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2018 | - | -$9.97 M(+54.4%) | -$24.62 M(+56.8%) |
| Mar 2018 | - | -$6.46 M(+26.2%) | -$15.70 M(+22.2%) |
| Dec 2017 | -$10.34 M(+992.0%) | -$5.12 M(+66.6%) | -$12.85 M(-224.2%) |
| Sep 2017 | - | -$3.07 M(+192.3%) | $10.35 M(+87.8%) |
| Jun 2017 | - | -$1.05 M(-70.9%) | $5.51 M(+735.8%) |
| Mar 2017 | - | -$3.61 M(-120.0%) | $659.00 K(-169.6%) |
| Dec 2016 | -$947.00 K(-35.0%) | $18.08 M(-328.6%) | -$947.00 K(-83.7%) |
| Sep 2016 | - | -$7.91 M(+34.1%) | -$5.80 M(+164.1%) |
| Jun 2016 | - | -$5.90 M(+13.1%) | -$2.19 M(+50.7%) |
| Mar 2016 | - | -$5.22 M(-139.4%) | -$1.46 M(-0.1%) |
| Dec 2015 | -$1.46 M(-95.6%) | $13.23 M(-407.2%) | -$1.46 M(-93.1%) |
| Sep 2015 | - | -$4.31 M(-16.6%) | -$21.28 M(-22.8%) |
| Jun 2015 | - | -$5.16 M(-1.1%) | -$27.55 M(-8.8%) |
| Mar 2015 | - | -$5.22 M(-20.8%) | -$30.21 M(-8.0%) |
| Dec 2014 | -$32.82 M(+219.6%) | -$6.59 M(-37.7%) | -$32.82 M(+3.0%) |
| Sep 2014 | - | -$10.58 M(+35.2%) | -$31.86 M(+30.5%) |
| Jun 2014 | - | -$7.82 M(-0.1%) | -$24.41 M(+37.3%) |
| Mar 2014 | - | -$7.83 M(+39.2%) | -$17.78 M(+73.2%) |
| Dec 2013 | -$10.27 M(+588.2%) | -$5.63 M(+79.5%) | -$10.27 M(+110.1%) |
| Sep 2013 | - | -$3.13 M(+162.6%) | -$4.89 M(+142.6%) |
| Jun 2013 | - | -$1.19 M(+281.5%) | -$2.02 M(+61.5%) |
| Mar 2013 | - | -$313.00 K(+27.2%) | -$1.25 M(+33.5%) |
| Dec 2012 | -$1.49 M(-61.5%) | -$246.00 K(-6.1%) | -$935.00 K(+35.7%) |
| Sep 2012 | - | -$262.00 K(-38.6%) | -$689.00 K(+61.4%) |
| Jun 2012 | - | -$427.00 K | -$427.00 K |
| Dec 2011 | -$3.88 M | - | - |
FAQ
- What is Arcturus Therapeutics Holdings annual EBITDA?
- What is the all time high annual EBITDA for Arcturus Therapeutics Holdings?
- What is Arcturus Therapeutics Holdings annual EBITDA year-on-year change?
- What is Arcturus Therapeutics Holdings quarterly EBITDA?
- What is the all time high quarterly EBITDA for Arcturus Therapeutics Holdings?
- What is Arcturus Therapeutics Holdings quarterly EBITDA year-on-year change?
- What is Arcturus Therapeutics Holdings TTM EBITDA?
- What is the all time high TTM EBITDA for Arcturus Therapeutics Holdings?
- What is Arcturus Therapeutics Holdings TTM EBITDA year-on-year change?
What is Arcturus Therapeutics Holdings annual EBITDA?
The current annual EBITDA of ARCT is -$77.40 M
What is the all time high annual EBITDA for Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings all-time high annual EBITDA is $13.70 M
What is Arcturus Therapeutics Holdings annual EBITDA year-on-year change?
Over the past year, ARCT annual EBITDA has changed by -$53.24 M (-220.30%)
What is Arcturus Therapeutics Holdings quarterly EBITDA?
The current quarterly EBITDA of ARCT is -$17.85 M
What is the all time high quarterly EBITDA for Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings all-time high quarterly EBITDA is $118.52 M
What is Arcturus Therapeutics Holdings quarterly EBITDA year-on-year change?
Over the past year, ARCT quarterly EBITDA has changed by -$1.39 M (-8.47%)
What is Arcturus Therapeutics Holdings TTM EBITDA?
The current TTM EBITDA of ARCT is -$69.68 M
What is the all time high TTM EBITDA for Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings all-time high TTM EBITDA is $116.11 M
What is Arcturus Therapeutics Holdings TTM EBITDA year-on-year change?
Over the past year, ARCT TTM EBITDA has changed by -$42.81 M (-159.38%)